Find insight on Novo Nordisk Foundation, ResMed, Johnson & Johnson, and more in the latest Market Talks covering Health Care.

Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from diverse populations.

Clinical trials of the first drugs designed with the help of artificial intelligence could commence this year, Google ...

The newly launched Global Energy Transition Forum aims to serve as an international focal point for renewables development ...

Events and conferences continue to connect Vancouver-based researchers with investors, as governments move money into ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on Wednesday, citing the Centers for Medicare & Medicaid Services.

It’s always a good sign when a couple of big deals are announced right before the conference, and this year we saw a doozie ...

Eli Lilly’s obesity drug Zepbound is now covered by Medicare for sleep apnea treatment, expanding access to the costly ...

Bio-IT World Conference & Expo, the premier annual gathering of 3,000 innovators at the intersection of IT and life sciences, ...